New drug combo tested for Hard-to-Treat cancers

NCT ID NCT06487858

Terminated Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Dec 15, 2025 · Last updated May 21, 2026 · Updated 23 times

Summary

This early-stage study tested a new drug called BGB-R046, alone or with another drug (tislelizumab), in 42 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530021, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Jining No1 Peoples Hospital West Branch

Jining, Shandong, 272000, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR